Clinical Laboratory

SARS-CoV-2 Ag Assay
LIAISON SARS-CoV-2 Ag

The LIAISON SARS-CoV-2 Ag assay is a chemiluminescence sandwich-immunoassay (CLIA) based technology for the quantitative determination of Nucleocapsid antigen protein from SARS-CoV-2 samples - in nasal swab (NS), nasopharyngeal swab (NPS) eluted in UTM/VTM directly from individuals who are suspected of COVID-19 by their healthcare provider within the first 10 days of the onset of symptoms. The assay is a unique quantitative solution to detect suspected COVID-19 patients, do contact tracing and rapidly implement isolation procedures for those patients who have been infected and might be able to spread SARS-CoV-2.

More details

SARS-CoV-2 IgM Assay
LIAISON SARS-CoV-2 IgM

The LIAISON SARS-CoV-2 IgM is a fully automated assay to be run on LIAISON X for detecting IgM antibody to the SARS-CoV-2 virus that causes COVID-19. The assay offers high sensitivity and specificity to ensure accurate results along the infection window.

More details

SARS-CoV-2 TrimericS IgG Assay
LIAISON SARS-CoV-2 TrimericS IgG Assay

The LIAISON SARS-CoV-2 TrimericS IgG Assay is a new generation of chemiluminescence immunoassay (CLIA), for the quantitative determination of anti-trimeric spike protein specific IgG antibodies to SARS-CoV-2 in human serum or plasma samples. The assay is intended as an aid in the diagnosis of CoVID-19 and to support the study of the immune status of infected patients by providing an indication of the presence of neutralizing IgG antibodies against SARS-CoV-2.

More details

SARS-CoV-2 S1/S2 IgG Assay
LIAISON SARS-CoV-2 S1/S2 IgG

The LIAISON SARS-CoV-2 S1/S2 IgG is a quantitative assay for the detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2. The fully automated solution with a throughput of up to 170 results/hour on LIAISON XL has high sensitivity and specificity to ensure accurate results. The quantitative assay with correlation to neutralizing antibodies can be used as an upstream pre-screening tool.

More details

News of DIASORIN

DiaSorin to Acquire Siemens' ELISA Immunodiagnostics Business

01 Aug 2017

DiaSorin S.p.A. has entered into an agreement to acquire Siemens Healthineers’ micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.

About DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tests are designed for hospital and private testing laboratories in the markets of immunodiagnostics and molecular diagnostics.

Description

The LIAISON Calprotectin test provides fast, reliable and automated detection of calprotectin in feces that is a marker used to help differentiate IBS (Irritable Bowel Syndrome) from IBD (Inflammatory Bowel Disease) and assess disease activity in IBD. Calprotectin is a heterocomplex composed of the calcium and zinc binding proteins S100A8 and S100A9, is resistant to enzymatic degradation, and can be easily measured in feces, making it ideal for direct detection by immunochemistry methods. Request Information

Features

• Number of tests: 100
• Extraction protocols: Device or weight
• Method: Sandwich Quantitative
• Solid Phase: MAb to Calprotectin Heterocomplex
• Conjugate: Monoclonal Antibody to S100A9 Subunit
• Label / Tracer: ABEI
• Sample volume: 5 μl
• Measuring range: without diluition: 5-800 ug/g Request Information

	* Required Information
	Logged in as
* Email	Already registered
Password	Wrong Password. If you have forgot password please click here.
To	DIASORIN (Calprotectin Test)
* Message

Member Login

Browse Products by Category

Browse Products by Category

DIASORIN

Covid-19 DIASORIN

Clinical Laboratory

News of DIASORIN

About DIASORIN

Calprotectin Test

Description:

Description

Features

Send A Message To This Supplier

More Products From This Supplier